BeStock  

Repligen RGEN

US equityMarket cap rank #1375Medical Instruments & Supplies
$163.81 −$6.48 (-3.81%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $163.81 0.00%
Open$169.61
Prev close$170.29
Day range$162.47 – $169.61
Volume697.7K
Market cap$10.47B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±6.1%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+17.9%
Worst reaction-5.9%

Stock move on the day after each report

-2.8%2023/Q4-3.6%2024/Q1+16.4%2024/Q2+6.5%2024/Q3+7.9%2024/Q4-2.9%2025/Q1+4.7%2025/Q2-5.9%2025/Q3-0.5%2025/Q4+6.3%2026/Q1+10.9%2026/Q2-2.4%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q327 Oct 2026Pre Market±12.6%-2.43%Within range
2026/Q228 Jul 2026Pre Market±11.7%+10.90%Within range
2026/Q15 May 2026Pre Market±10.4%+6.26%Within range
2025/Q424 Feb 2026Pre Market±11.4%-0.54%Within range
2025/Q328 Oct 2025Pre Market±10.5%-5.92%Within range
2025/Q229 Jul 2025Pre Market±11.3%+4.72%Within range
2025/Q129 Apr 2025Pre Market±17.5%-2.92%Within range
2024/Q420 Feb 2025Pre Market±10.1%+7.92%Within range
2024/Q312 Nov 2024Pre Market±12.7%+6.51%Within range
2024/Q230 Jul 2024Pre Market±12.3%+16.37%Bigger than priced
2024/Q11 May 2024Pre Market±10.9%-3.56%Within range
2023/Q421 Feb 2024Pre Market±10.5%-2.82%Within range
2023/Q331 Oct 2023Pre Market±14.0%+17.86%Bigger than priced
2023/Q22 Aug 2023Pre Market±11.7%+2.01%Within range
2023/Q12 May 2023Pre Market±12.4%+2.40%Within range
2022/Q422 Feb 2023Pre Market±14.3%-4.51%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Filtration Products$95.57M 45.7%
  • Chromatography products$53.56M 25.6%
  • Proteins products$32.11M 15.3%
  • Process analytics products$27.76M 13.3%
  • Other$271,000.00 0.1%
  • Royalty and other income$44,000.00 0.0%

Latest reported quarter: Q3, ended Sep 2026

Revenue$209.31M+10.9% YoY
Operating profit$12.96M+2.2% YoY
Net profit-$38.43M-357.7% YoY
Diluted EPS-$0.68-361.5% YoY
Free cash flow$37.82M-11.5% YoY
Operating cash flow$43.10M

Revenue, last 8 quarters

$167.5MDec '24$169.2MMar '25$182.4MJun '25$188.8MSep '25$197.9MDec '25$194.3MMar '26$204.1MJun '26$209.3MSep '26

Net profit, last 8 quarters

$-33.9MDec '24$5.8MMar '25$14.9MJun '25$14.9MSep '25$13.3MDec '25$8.3MMar '26$5.0MJun '26$-38.4MSep '26

Profitability & balance sheet

Gross margin53.5%
Operating margin7.6%
Net margin-1.5%
Return on equity-0.6%
Return on assets-0.4%
Return on invested capital0.1%
Current ratio9.88
Liabilities / assets28.5%
Cash & investments$862.98M
Total debt$671.84M
Net cash (debt)$191.14M
Free cash flow / sales13.1%

Discussion

No comments yet — be the first to weigh in on RGEN.

Sign in to join the discussion.

Scroll to Top